Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Revenue (2020 - 2025)

Ovid Therapeutics filings provide 6 years of Revenue readings, the most recent being $718000.0 for Q4 2025.

  • Quarterly Revenue rose 844.74% to $718000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Mar 2026, up 1199.64% year-over-year, with the annual reading at $7.3 million for FY2025, 1181.27% up from the prior year.
  • Revenue hit $718000.0 in Q4 2025 for Ovid Therapeutics, up from $132000.0 in the prior quarter.
  • Across five years, Revenue topped out at $208.4 million in Q1 2021 and bottomed at $11102.0 in Q3 2022.
  • Average Revenue over 5 years is $13.6 million, with a median of $137000.0 recorded in 2023.
  • The largest annual shift saw Revenue plummeted 99.57% in 2022 before it skyrocketed 3611.24% in 2025.
  • Ovid Therapeutics' Revenue stood at $208.4 million in 2021, then tumbled by 99.98% to $46280.0 in 2022, then surged by 206.83% to $142000.0 in 2023, then tumbled by 46.48% to $76000.0 in 2024, then surged by 844.74% to $718000.0 in 2025.
  • Per Business Quant, the three most recent readings for OVID's Revenue are $718000.0 (Q4 2025), $132000.0 (Q3 2025), and $6.3 million (Q2 2025).